Topspin Fund L.P. 3
3 · RAPT Therapeutics, Inc. · Filed Nov 12, 2019
Insider Transaction Report
Form 3
Topspin Fund L.P.
10% Owner
Holdings
Series C-2 Preferred Stock
→ Common Stock (155,201 underlying)- (indirect: See Footnote)
Series B Preferred Stock
→ Common Stock (1,641,666 underlying) Series C Preferred Stock
→ Common Stock (363,504 underlying)
Footnotes (3)
- [F1]Each share of Series B, C and C-2 Preferred Stock shown in Column 3 is convertible into one-sixth (1/6th) shares of Common Stock at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date.
- [F2]The shares are held directly by Topspin Biotech Fund II, L.P. LG Management, LLC, the general partner of Topspin Biotech Fund II, L.P., may be deemed to have voting and dispositive power with respect to the shares. Leo A. Guthart, the managing member of LG Management, LLC, may also be deemed to have voting and dispositive power with respect to the shares. Each of LG Management, LLC and Leo A. Guthart disclaims beneficial ownership of the shares, except to the extent of their respective indirect pecuniary interests in such shares.
- [F3]The shares are held directly by Topspin Fund L.P. LG Management, LLC, the general partner of Topspin Fund L.P., may be deemed to have voting and dispositive power with respect to the shares. Leo A. Guthart, the managing member of LG Management, LLC, may also be deemed to have voting and dispositive power with respect to the shares. Each of LG Management, LLC and Leo A. Guthart disclaims beneficial ownership of the shares, except to the extent of their respective indirect pecuniary interests in such shares.